Background: Isavuconazole (ISA) is a novel, broad-spectrum, triazole antifungal in development for treatment of invasive fungal disease. Fusarium and Scedosporium spp. are associated with high mortality in immunocompromised patients; however, treatment options are limited. We report outcomes in a subset of patients enrolled in the VITAL and SECURE trials with invasive mold disease (IMD) caused by these pathogens.
Methods: VITAL and SECURE were Phase 3 trials that evaluated efficacy and safety of ISA treatment in patients with IMD. Dosages were ISA 200 mg TID for 2 days followed by 200 mg QD (IV or PO). Proven/probable IMD (EORTC/MSG criteria), and overall response at end of treatment (EOT) were determined by independent, data-review committees. Mortality rates, safety and tolerability were also analyzed.
Results: Demographics and outcomes data are shown in Table A1.
- ICAAC 54th (2014)